In the accompanying article, we describe the creation of novel cell lines derived from RIN 1046-38 rat insulinoma cells by stable transfection with combinations of genes encoding human insulin, GLUT2, and glucokinase. Herein we describe the regulation of insulin secretion and glucose metabolism in these new cell lines. A cell line (βG I/17) expressing only the human proinsulin transgene exhibits a clear increase in basal insulin production (measured in the absence of secretagogues) relative to parental RIN 1046-38 cells. βG I/17 cells engineered for high levels of GLUT2 expression and a twofold increase in glucokinase activity ([βG 49/206) or engineered for a 10-fold increase in glucokinase activity alone (βG 40/110) exhibit a 66% and 80% suppression in basal insulin secretion relative to βG I/17 cells, respectively. As a result, βG 49/206 and βG 40/110 cells exhibit potent insulin-secretory responses to glucose alone (6.1- and 7.6-fold, respectively) or to glucose plus isobutylmethylxanthine (10.8- and 15.1-fold, respectively) that are clearly larger than the corresponding responses of βG I/17 or parental RIN 1046-38 cells. βG 49/206 and βG 40/110 cells also exhibit a rapid and sustained response to glucose plus isobutylmethylxanthine in perifusion studies that is clearly larger in magnitude than that of the two control lines. Glucose dose-response studies show that both engineered and non-engineered lines respond maximally to submillimolar concentrations of glucose and that βG 49/206 cells are the most sensitive to low concentrations of the hexose, consistent with their clearly elevated rate of ]5-3H]glucose usage. Finally, 5-thioglucose, a potent inhibitor of low-Km hexokinases, most effectively normalizes glucose concentration dependence for insulin secretion in the cell line with highest glucokinase expression (βG 40/110). We conclude that GLUT2 and/or glucokinase expression imposes tight regulation of basal insulin secretion in cell lines that overexpress human proinsulin, allowing a marked improvement in the range of secretagogue responsiveness in such cells.
Skip Nav Destination
Article navigation
Original Articles|
June 01 1997
Regulation of Insulin Secretion From Novel Engineered Insulinoma Cell Lines
Hans E Hohmeier;
Hans E Hohmeier
From the Gifford Laboratories for Diabetes Research and Departments of Biochemistry and Internal Medicine, University of Texas Southwestern Medical Center
Dallas, Texas
Search for other works by this author on:
Hector BeltrandelRio;
Hector BeltrandelRio
From the Gifford Laboratories for Diabetes Research and Departments of Biochemistry and Internal Medicine, University of Texas Southwestern Medical Center
Dallas, Texas
Search for other works by this author on:
Samuel A Clark;
Samuel A Clark
BetaGene, Inc.
Dallas, Texas
Search for other works by this author on:
Rosemarie Henkel-Rieger;
Rosemarie Henkel-Rieger
BetaGene, Inc.
Dallas, Texas
Search for other works by this author on:
Karl Normington;
Karl Normington
BetaGene, Inc.
Dallas, Texas
Search for other works by this author on:
Christopher B Newgard
Christopher B Newgard
From the Gifford Laboratories for Diabetes Research and Departments of Biochemistry and Internal Medicine, University of Texas Southwestern Medical Center
Dallas, Texas
Search for other works by this author on:
Address correspondence and reprint requests to Christopher B. Newgard, PhD, Gifford Laboratories for Diabetes Research, Room Y8.212, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235.
1
K.N., S.C., C.Q., and C.B.N. hold stock in BetaGene, a company involved in development of cell-based methods for delivery of therpeutic products. C.B.N. is also the founding scientist and a member of the company's board of directors.
2
BSA, bovine serum albumin; GSIS, glucose-stimulated insulin secretion; HBBSS, HEPES/bicarbonate-buffered salt solution; IBMX, isobutylmethylxanthine; PLC, phospholipase.
Diabetes 1997;46(6):968–977
Article history
Received:
October 24 1996
Revision Received:
January 16 1997
Accepted:
January 16 1997
PubMed:
9166667
Citation
Hans E Hohmeier, Hector BeltrandelRio, Samuel A Clark, Rosemarie Henkel-Rieger, Karl Normington, Christopher B Newgard; Regulation of Insulin Secretion From Novel Engineered Insulinoma Cell Lines. Diabetes 1 June 1997; 46 (6): 968–977. https://doi.org/10.2337/diab.46.6.968
Download citation file:
82
Views